Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialAndrew McGarry, Karl Kieburtz, Kevin J. Klos et al.|The Lancet Neurology|2023Cited by 128
Dominant missense variants in SREBF2 are associated with complex dermatological, neurological, and skeletal abnormalitiesMatthew J. Moulton, Kosuke Izumi, Oguz Kanca et al.|Genetics in Medicine|2024Cited by 3